Amphastar Q3 Revenue Up 8% to $207.6M; Board Adds $50M to Buyback
AMPH sits 81% above its 52-week low of $16.645.
Summary
Amphastar reported Q3 revenue of $207.6 million (up 8%) and GAAP EPS of $0.87, but gross margin slipped to 48.0% on IMS remediation costs and weaker pricing. The board also authorized a $50 million increase to the share buyback program.
Key Events · Earnings and Guidance · AMPH
-
Q3 Revenue Rises 8% to $207.6M
Net revenues came in at $207.6 million versus $191.8 million a year ago, led by record BAQSIMI sales of $58.8 million (up 10%) and Primatene MIST at $31.5 million (up 9%).
-
GAAP EPS Nearly Doubles to $0.87
GAAP net income was $37.8 million, or $0.87 per diluted share, against $17.4 million, or $0.37, a year ago; adjusted non-GAAP EPS was $1.14.
-
Gross Margin Slips to 48.0%
Gross margin fell from 51.4% on lower average selling prices for BAQSIMI, glucagon and epinephrine multi-dose vials, plus higher IMS remediation and facility expansion costs.
-
Board Adds $50M to Buyback
On November 4, 2026 the board authorized a $50 million increase to the share buyback program, aimed primarily at offsetting dilution from equity compensation.
Analysis · AMPH · Life Sciences
Top-line growth of 8% and a near-doubling of GAAP net income to $37.8 million look strong, but the quality is mixed: gross margin fell to 48.0% from 51.4% as IMS remediation costs and lower pricing on BAQSIMI, glucagon and epinephrine ate into profitability. The bigger surprise is the board's $50 million buyback increase on November 4, which management frames as offsetting equity-compensation dilution — a real capital-return decision layered onto an earnings release. With the stock near its 52-week high, the buyback authorization supports the shares, while margin compression and ongoing FDA warning-letter remediation at IMS remain the swing factors for the next several quarters.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMPH was trading at $30.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $16.65 to $29.52. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.